Lukas A. Huber

Biographical sketch

I studied medicine at the University of Innsbruck. I joined the laboratory of Kai Simons at EMBL in Heidelberg (Germany) as postdoc in epithelial biology until 1994. I then moved to the University of Geneva (Switzerland) and worked in the laboratory of Jean Gruenberg on endocytosis in epithelial cells. In 1996 I started my own laboratory at the I.M.P. in Vienna (Austria) and in 2002 I got appointed as professor and head of the Division of Cell Biology and in 2005 as scientific director of the Biocenter of Innsbruck Medical University (Austria). My research interests have expanded to understanding the spatial and temporal resolution of signaling mechanisms in mammalian cells applying molecular cell biology, mouse genetics and functional proteomics. I initiated and coordinated the FP6 EU program GROWTHSTOP, the Austrian Proteomics Platform of the Austrian Genome Program (GEN-AU), a special research program in Innsbruck entitled "Cell proliferation and Cell Death in Tumors" – SFB021 of the Austrian Science Fund (FWF) and actively participate in several EU programs and also coordinate programs. Since 2009 I am also CSO of the ONCOTYROL center of personalized cancer medicine in Innsbruck, Austria and since 2012 founder and scientific director of the Austrian Drug Screening Institute (ADSI).

Curriculum vitae

Biozentrum der Medizinischen Universität Innsbruck
Sektion für Zellbiologie
Innrain 80-82
A-6020 Innsbruck
Austria
Tel: +43-512-9003-70170
Web: http://biocenter.i-med.ac.at/
http://www.oncotyrol.at/
http://www.adsi.ac.at/
Email lukas.a.huber@i-med.ac.at
ORCID: 0000-0003-1116-2120

Date of birth	4 July 1961
Place of birth	Vienna, Austria
Citizenship	Austrian

Education

1980	Matura, Humanistisches Gymnasium Paulinum, Schwaz, Austria
1989	MD, Medical School, University of Innsbruck, Austria

Career History

1987-1989	M.D. Thesis, "Immunology of Ageing: Immuno regulatory Properties of Lipoproteins". Institute for General and Experimental Pathology, University of Innsbruck, Medical School, Austria, Prof. Dr. Georg Wick
1990-1993	Postdoc at the European Molecular Biology Laboratory (EMBL), Cell Biology Program, Heidelberg, Prof. Dr. Kai Simons
1993-1995	Maître Assistant, Département de Biochimie, Université de Genève, Sciences II, Genève, Switzerland, Prof. Dr. Jean Gruenberg
1995	Venia Legendi, in General and Experimental Pathology University of Innsbruck, Medical School
1996-2002	Group Leader, Institute of Molecular Pathology, IMP, Vienna, Austria
2002	Call as Full Professor to Innsbruck Medical University
2002 to 2004	Head of Histology and Molecular Cell Biology, Innsbruck Medical University
since 2004	Director Division of Cell Biology, Biocenter, Medical University Innsbruck

2005-2013	Director and Head of the Biocenter, Medical University Innsbruck
since 2005	Head of Research Infrastructure Commission Innsbruck Medical University
since 2007	Member of the Senat of Medical University Innsbruck
2007-2008	Co-Director of the Integrated Research and Therapy Center (IFTZ), Innsbruck
since 2009	CSO, Center for Personalized Medicine, ONCOTYROL, Innsbruck
since 2009	Chair of Ilse and Helmut Wachter Foundation (Wachter Prize)
2010-2014	Austrian representative and Steering Committee member to the ESF Research Networking Program on "Frontiers in Functional Genomics"
2012	Appointment as Professor and Director Systems Pharmacology, University College Dublin, Ireland -- declined
since 2012	Director of the Austrian Drug Screening Institute under the patronage of the Austrian Academy of Sciences (ÖAW)
since 2013	Austrian delegate in the International Agency for Research on Cancer-IARC
since 2014	Scientific Council (WHO)
since 2015	Vize President, Austrian Association of Molecular Life Sciences and
since 2015	Biotechnology (ÖGMBT)
	Chair of Management Board of Wings4Innovation, Austria
	Advisory Board Member Max Planck Institute for Infection Biology, Berlin

Fellowships, Awards	Johnson&Johnson focused giving grant (1995), Research Price in Cell Biology, DGZ, German Society (1995), Hoechst Price (1990), Friedrich Tuba Preis für Alternsforschung 1996, CAST Technology Award 2007
Publications	h-factor=59, cited >12.900 times, average citation per item >45 Google Scholar link
Patents	US 12/994,491,
Other Functions	Senior Editor **Proteomics, Proteomics Clinical Applications, FEBS Letters;** Associate Editor Current and Molecular Life Sciences, Current Opinion in Molecular Therapeutics, Current Signal Transduction Therapy, Frontiers Cell and Developmental Biology**.** **Coordinator of SFB021** „Cell Proliferation and Cell Death in Tumors", Austrian Proteomics Platform (GEN-AU), GROWTHSTOP (EU, FP6, LSHC-CT-2006-037731), ONCOTYROL - Center for Personalized Cancer Therapy, Austrian Drug Screening Institute – ADSI**.** **Reviewing boards**: DFG, Cancer UK, BAYGENE, EUROSTARS, Max Planck, BMBF program "National Consortium for Translational Cancer Research", BMBF program "Systems Medicine", International Agency for Research on Cancer-IARC, ÖNB, Research Agency of Lower Austria, Swiss National Science Foundation,
Research Interests	Spatio-temporal regulation of signal transduction through scaffold complexes and their subcellular localization, protein transport and sorting, proteomics, mouse genetics, translational cancer research, congenital enteropathies, lysosomal diseases, orphan diseases, drug screening and development

Funds obtained (in €, 5 most important ones)

SFB021 Cell proliferation and Cell death in Tumors *Coordination project+Project part02+Tiroler Zukunftsstiftung*	1.019.280 +580.125 +486.847	FWF FWF Tyrol	2011-2013
Doktoratskolleg (W11), Molecular Cell Biology and Oncology, 3rd & 4rd funding period	247.000	FWF-Med. Uni. Innsbruck	2012-2017
ADSI-Austrian Drug Screening Institute	2.750.000	BMW, Bionorica, Tyrol	2016-2018
INTERREG ITAT1009 – Precision Cancer Medicine	201.997 (ADSI) 142.789 (MUI)	EU	2017-2019
Structure-Function analysis of the late endosomal LAMTOR complex	410.760	FWF (P 26682)	2014-2017

PhD students since 2013

Name (PhD Program)	Title of PhD thesis	Start	Graduation	publications
Cornelia Thoeni (co-supervision with TM) (MCB)	Molecular mechanisms in the pathogenesis of Microvillus Inclusion Disease (MVID)	2011	2013	4
Julia Scheffler (MCB)	LAMTOR regulates dendritic cell homeostatis through Flt3 dependent mTOR signaling	2009	2014	5
Georg Friedrich Vogel co-supervision with TM) (MCB)	Myo5b-Syntaxin3 interplay drives cargo-selective apical exocytosis in enterocaytes	2010	2015	8
Pzremislav Filipek (MCB)	Molecular and functional characterization of C7orf59 and HBXIP as novel LAMTOR interacting proteins	2012	2017 (April)	3
Teodor Yordanov (MCBO)	Molecular analysis of the LAMTOR complex: merging point of different signaling pathways on late endosomes	2013	ongoing	2
Gudrun Liebscher (MCBO)	LAMTOR complex in the regulation of fat metabolism	2015	ongoing	0
Katharina Klee (co-supervision with TM) (MCBO)	Investigation of cargo-selective apical transport in polarized epithelial cells	2016	ongoing	1
Iris Krainer (co-supervision with TM) (MCBO)	Establishment and analyses of organoids from patients with congenital entheropathies and liver diseases	2015	ongoing	1

International collaborators

	Project	**Joint public.**	**lab for stay abroad**
Sabine Middendorp (Division of Paediatrics, UMC Utrecht, The Netherlands)	Microvillus inclusion disease (MVID)	3	yes
Ernest Cutz (Department of Pediatrics Hospital for Sick Children, Toronto, Canada)	Microvillus inclusion disease (MVID)	2 (+1 submitted)	yes
Judith Klumperman (Department of Cell Biology and The Cell Microscopy Centre, UMC Utrecht, The Netherlands)	Electron microscopy and protein transport/sorting in congenital enthropathies	2 (+1 submitted)	yes

International network: INTERREG- PreCanMed Precision cancer medicine platform

Lukas A. Huber; 10 most important scientific publications

1. Araujo MEG, Naschberger A, Fürnrohr BG, Stasyk T, Dunzendorfer-Matt T, Lechner S, Welti S, Kremser L, Shivalingaiah G, Offterdinger M, Lindner HH, **Huber LA***, Scheffzek K.* Crystal structure of the human lysosomal mTORC1 scaffold complex and its impact on signaling. **Science** 2017; doi: 10.1126/science.aao1583. Epub 2017 Sep 21.**equal contribution as corresponding authors*

2. Filipek PA, Araujo MEG, Vogel GF, De Smet CH, Eberharter D, Rebsamen M, Rudashevskaya EL, Kremser L, Yordanov T, Tschaikner P, Fürnrohr BG, Lechner S, Dunzendorfer-Matt T, Scheffzek K, Bennett KL, Surperti-Furga G, Lindner HH, Stasyk T, **Huber LA**. LAMTOR/Ragulator is a negative regulator of Arl8b- and BORC-dependent late endosomal positioning. **J Cell Biol**. 2017; doi: 10.1083/jcb.201703061. Epub 2017 Oct 9.

3. Vogel GF, Klee KM, Janecke AR, Müller T, Hess MW, **Huber LA**. Cargo-selective apical exocytosis in epithelial cells is conducted by Myo5B, Slp4a, Vamp7, and Syntaxin 3. **J Cell Biol.** 2015; 211:587-604. doi: 10.1083/jcb.201506112.

4. Rebsamen M, Pochini L, Stasyk T, de Araujo ME, Galluccio M, Kandasamy RK,Snijder B, Fauster A, Rudashevskaya EL, Bruckner M, Scorzoni S, Filipek PA, HuberKV, Bigenzahn JW, Heinz LX, Kraft C, Bennett KL, Indiveri C, **Huber LA**, Superti-Furga G. SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1. **Nature**. 2015; 519:477-81. doi: 10.1038/nature14107.

5. Scheffler JM, Sparber F, Tripp CH, Herrmann C, Humenberger A, Blitz J, Romani N, Stoitzner P, **Huber LA**. LAMTOR2 regulates dendritic cell homeostasis through FLT3-dependent mTOR signaling. **Nat Commun**. 2014; 5:5138. doi: 10.1038/ncomms6138.

6. Schiefermeier N, Scheffler JM, de Araujo ME, Stasyk T, Yordanov T, Ebner HL, Offterdinger M, Munck S, Hess MW, Wickström SA, Lange A, Wunderlich W, Fässler R, Teis D, **Huber LA**. The late endosomal p14-MP1 (LAMTOR2/3) complex regulates focal adhesion dynamics during cell migration. **J Cell Bio***l*. 2014; 205:525-40. doi: 10.1083/jcb.201310043.

7. Müller T, Hess MW, Schiefermeier N, Pfaller K, Ebner HL, Heinz-Erian P, Ponstingl H, Partsch J, Röllinghoff B, Köhler H, Berger T, Lenhartz H, Schlenck B, Houwen RJ, Taylor CJ, Zoller H, Lechner S, Goulet O, Utermann G, Ruemmele FM, **Huber LA***, Janecke AR*. MYO5B mutations cause microvillus inclusion disease and disrupt epithelial cell polarity. **Nat Genet**. 2008; 40:1163-5. doi: 10.1038/ng.225. **equal contribution as corresponding authors*

8. Teis D, Taub N, Kurzbauer R, Hilber D, de Araujo ME, Erlacher M, Offterdinger M, Villunger A, Geley S, Bohn G, Klein C, Hess MW, **Huber LA**. p14-MP1-MEK1 signaling regulates endosomal traffic and cellular proliferation during tissue homeostasis. **J Cell Biol**. 2006; 175:861-8. doi: 10.1083/jcb.200607025.

9. Teis D, Wunderlich W, **Huber LA**. Localization of the MP1-MAPK scaffold complex to endosomes is mediated by p14 and required for signal transduction. **Dev Cell.** 2002; 3:803-14. doi: 10.1016/S1534-5807(02)00364-7.

10. Wunderlich W, Fialka I, Teis D, Alpi A, Pfeifer A, Parton RG, Lottspeich F, **Huber LA**. A novel 14-kilodalton protein interacts with the mitogen-activated protein kinase scaffold mp1 on a late endosomal/lysosomal compartment. **J Cell Biol. 2001**; 152:765-76. doi: 10.1083/jcb.152.4.765.

Lukas A. Huber; all publications since 2013

1. Hess MW, Vogel GF, Yordanov TE, Witting B, Gutleben K, Ebner HL, de Araujo MEG, Filipek P, **Huber LA**. Combining high-pressure freezing with pre-embedding immunogold electron microscopy and tomography. **Traffic**. 2018 Apr 19. doi: 10.1111/tra.12575. [Epub ahead of print] PubMed PMID: 29673018.

2. Stasyk T, **Huber LA**. DIGE-based phosphoproteomic analysis. **Methods Mol Biol**. 2018;1664:79-86. doi: 10.1007/978-1-4939-7268-5_7.

3. Araujo MEG, Naschberger A, Fürnrohr BG, Stasyk T, Dunzendorfer-Matt T, Lechner S, Welti S, Kremser L, Shivalingaiah G, Offterdinger M, Lindner HH, **Huber LA***, Scheffzek K.* Crystal structure of the human lysosomal mTORC1 scaffold complex and its impact on signaling. **Science** 2017; doi: 10.1126/science.aao1583. Epub 2017 Sep 21.**equal contribution as corresponding authors*

4. Filipek PA, Araujo MEG, Vogel GF, De Smet CH, Eberharter D, Rebsamen M, Rudashevskaya EL, Kremser L, Yordanov T, Tschaikner P, Fürnrohr BG, Lechner S, Dunzendorfer-Matt T, Scheffzek K, Bennett KL, Surperti-Furga G, Lindner HH, Stasyk T, **Huber LA**. LAMTOR/Ragulator is a negative regulator of Arl8b- and BORC-dependent late endosomal positioning. **J Cell Biol**. 2017; doi: 10.1083/jcb.201703061. Epub 2017 Oct 9.

5. Vogel GF, van Rijn JM, Krainer IM, Janecke AR, Posovzsky C, Cohen M, Searle C, Jantchou P, Escher JC, Patey N, Cutz E, Müller T, Middendorp S, Hess MW, **Huber LA**. Disrupted apical exocytosis of cargo vesicles causes enteropathy in FHL5 patients with Munc18-2 mutations. **JCI Insight.** 2017; 2:e94564. doi: 10.1172/jci.insight.94564.

6. Coassin S, Erhart G, Weissensteiner H, Eca Guimaraees de Araujo M, Lamina C, Schönherr S, Forer L, Haun M, Losso JL, Kötgen A, Schmidt K, Utermann G, Peters A, Gieger C, Strauch K, Finkenstedt A, Bale R, Zoller H, Paulweber B, Eckardt KU, Hüttenhofer A, **Huber LA**, Kronenberg F. A novel but frequent variant in LPA KIV-2 is associated with a pronounced Lp(a) and cardiovascular risk reduction. **Eur Heart J**. 2017; in press. doi: 10.1093/eurheartj/ehx174.

7. Vogel GF, Janecke AR, Krainer IM, Gutleben K, Witting B, Mitton SG, Mansour S, Ballauff A, Roland JT, Engevik AC, Cutz E, Müller T, Goldenring JR, **Huber LA**, Hess MW. Abnormal Rab11-Rab8-vesicles cluster in enterocytes of patients with microvillus inclusion disease. **Traffic**. 2017; 18:453-64. doi: 10.1111/tra.12486.

8. Janecke AR, Xu R, Steichen-Gersdorf E, Waldegger S, Entenmann A, Giner T, Krainer I, **Huber LA**, Hess MW, Frishberg Y, Barash H, Tzur S, Schreyer-Shafir N, Sukenik-Halevy R, Zehavi T, Raas-Rothschild A, Mao C, Müller T. Deficiency of the sphingosine-1-phosphate lyase SGPL1 is associated with congenital nephrotic syndrome and congenital adrenal calcifications. **Hum Mutat.** 2017;38:365-72. doi: 10.1002/humu.23192.

9. **Huber LA**. New Mouse Models for Microvillus Inclusion Disease (MVID): Where Do the Inclusions Come From and Are They Cause or Consequence? **Cell Mol Gastroenterol Hepatol.** 2016;2:112-3. doi: 10.1016/j.jcmgh.2015.12.012.

10. Lammirato A, Patsch K, Feiereisen F, Maly K, Nofziger C, Paulmichl M, Hackl H, Trajanoski Z, Valovka T, **Huber LA**, Vietor I. TIS7 induces transcriptional cascade of methylosome components required for muscle differentiation. **BMC Biol.** 2016;14:95. doi: 10.1186/s12915-016-0318-6.

11. Reintjes A, Fuchs JE, Kremser L, Lindner HH, Liedl KR, **Huber L**A, Valovka T. Asymmetric arginine dimethylation of RelA provides a repressive mark to modulate TNFa/NF-kB response. **Proc Natl Acad Sci USA.** 2016;113:4326-31. doi: 10.1073/pnas.1522372113.

12. Vogel GF, Hess MW, Pfaller K, **Huber LA**, Janecke AR, Müller T. Towards understanding microvillus inclusion disease. **Mol Cell Pediatr**. 2016; 3:3. doi: 10.1186/s40348-016-0031-0.

13. **Huber LA**, Teis D. Lysosomal signaling in control of degradation pathways. **Curr Opin Cell Biol.** 2016; 39:8-14. doi: 10.1016/j.ceb.2016.01.006.

14. de Araujo ME, Lamberti G, **Huber LA**. Purification of Early and Late Endosomes. **Cold Spring Harb Protoc.** 2015; 2015: pdb.top074443. doi: 10.1101/pdb.top074443.

15. Lamberti G, de Araujo ME, **Huber LA**. Isolation of Macrophage Early and Late Endosomes by Latex Bead Internalization and Density Gradient Centrifugation. **Cold Spring Harb Protoc.** 2015; 2015:pdb.prot083451. doi: 10.1101/pdb.prot083451.

16. Vogel GF, Klee KM, Janecke AR, Müller T, Hess MW, **Huber LA**. Cargo-selective apical exocytosis in epithelial cells is conducted by Myo5B, Slp4a, Vamp7, and Syntaxin 3. **J Cell Biol**. 2015; 211:587-604. doi: 10.1083/jcb.201506112.

17. de Araujo ME, Lamberti G, **Huber LA**. Isolation of Early and Late Endosomes by Density Gradient Centrifugation. **Cold Spring Harb Protoc**. 2015; 2015:1013-6. doi: 10.1101/pdb.prot083444.

18. de Araujo ME, Lamberti G, **Huber LA**. Homogenization of Mammalian Cells. **Cold Spring Harb Protoc.** 2015; 2015:1009-12. doi: 10.1101/pdb.prot083436.

19. Stasyk T, **Huber LA**. Spatio-Temporal Parameters of Endosomal Signaling in Cancer: Implications for New Treatment Options. **J Cell Biochem.** 2016; 117:836-43. doi: 10.1002/jcb.25418.

20. Schneeberger K, Vogel GF, Teunissen H, van Ommen DD, Begthel H, El Bouazzaoui L, van Vugt AH, Beekman JM, Klumperman J, M√ºller T, Janecke A, Gerner P, **Huber LA**, Hess MW, Clevers H, van Es JH, Nieuwenhuis EE, Middendorp S. An inducible mouse model for microvillus inclusion disease reveals a role for myosin Vb in apical and basolateral trafficking. **Proc Natl Acad Sci USA.** 2015; 112:12408-13. doi: 10.1073/pnas.1516672112.

21. Vogel GF, Ebner HL, de Araujo ME, Schmiedinger T, Eiter O, Pircher H, Gutleben K, Witting B, Teis D, **Huber LA**, Hess MW. Ultrastructural Morphometry Points to a New Role for LAMTOR2 in Regulating the Endo/Lysosomal System. **Traffic.** 2015; 16:617-34. doi: 10.1111/tra.12271.

22. Rebsamen M, Pochini L, Stasyk T, de Araujo ME, Galluccio M, Kandasamy RK, Snijder B, Fauster A, Rudashevskaya EL, Bruckner M, Scorzoni S, Filipek PA, Huber KV, Bigenzahn JW, Heinz LX, Kraft C, Bennett KL, Indiveri C, **Huber LA**, Superti-Furga G. SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1. **Nature**. 2015; 519:477-81. doi: 10.1038/nature14107.

23. Scheffler JM, Sparber F, Tripp CH, Herrmann C, Humenberger A, Blitz J, Romani N, Stoitzner P, **Huber LA**. LAMTOR2 regulates dendritic cell homeostasis through FLT3-dependent mTOR signalling. **Nat Commun**. 2014; 5:5138. doi: 10.1038/ncomms6138.

24. Csiszar A, Kutay B, Wirth S, Schmidt U, Macho-Maschler S, Schreiber M, Alacakaptan M, Vogel GF, Aumayr K, **Huber LA**, Beug H. Interleukin-like epithelial-to-mesenchymal transition inducer activity is controlled by proteolytic processing and plasminogen-urokinase plasminogen activator receptor system-regulated secretion during breast cancer progression. **Breast Cancer Res.** 2014; 16:433. doi: 10.1186/s13058-014-0433-7.

25. Sparber F, Tripp CH, Komenda K, Scheffler JM, Clausen BE, **Huber LA**, Romani N,Stoitzner P. The late endosomal adaptor molecule p14 (LAMTOR2) regulates TGFb1-mediated homeostasis of Langerhans cells. **J Invest Dermatol**. 2015; 135:119-29. doi: 10.1038/jid.2014.324.

26. Schiefermeier N, Scheffler JM, de Araujo ME, Stasyk T, Yordanov T, Ebner HL, Offterdinger M, Munck S, Hess MW, Wickström SA, Lange A, Wunderlich W, Fässler R, Teis D, **Huber LA**. The late endosomal p14-MP1 (LAMTOR2/3) complex regulates focal adhesion dynamics during cell migration. **J Cell Biol**. 2014; 205:525-40. doi: 10.1083/jcb.201310043.

27. Thauerer B, Voegele P, Hermann-Kleiter N, Thuille N, de Araujo ME, Offterdinger M, Baier G, **Huber LA**, Baier-Bitterlich G. LAMTOR2-mediated modulation of NGF/MAPK activation kinetics during differentiation of PC12 cells. **PLoS One**. 2014; 9:e95863. doi: 10.1371/journal.pone.0095863.

28. Wiegerinck CL, Janecke AR, Schneeberger K, Vogel GF, van Haaften-Visser DY, Escher JC, Adam R, Thoeni CE, Pfaller K, Jordan AJ, Weis CA, Nijman IJ, Monroe GR, van Hasselt PM, Cutz E, Klumperman J, Clevers H, Nieuwenhuis EE, Houwen RH, van Haaften G, Hess MW, **Huber LA**, Stapelbroek JM, Müller T, Middendorp S. Loss of syntaxin 3 causes variant microvillus inclusion disease. **Gastroenterology.** 2014; 147:65-68.e10. doi: 10.1053/j.gastro.2014.04.002.

29. Schnaiter S, Fürst B, Neu J, Wieczek F, Orfi L, Keri G, **Huber LA**, Wunderlich W. Screening for MAPK modulators using an in-cell western assay. **Methods Mol Biol.** 2014; 1120:121-9. doi: 10.1007/978-1-62703-791-4_8.

30. Scheffler JM, Schiefermeier N, **Huber LA**. Mild fixation and permeabilization protocol for preserving structures of endosomes, focal adhesions, and actin filaments during immunofluorescence analysis. **Methods Enzymol.** 2014; 535:93-102. doi: 10.1016/B978-0-12-397925-4.00006-7.

31. Thoeni CE, Vogel GF, Tancevski I, Geley S, Lechner S, Pfaller K, Hess MW, Müller T, Janecke AR, Avitzur Y, Muise A, Cutz E, **Huber LA**. Microvillus inclusion disease: loss of Myosin vb disrupts intracellular traffic and cell polarity. **Traffic.** 2014; 15:22-42. doi: 10.1111/tra.12131.

32. Sparber F, Scheffler JM, Amberg N, Tripp CH, Heib V, Hermann M, Zahner SP, Clausen BE, Reizis B, **Huber LA**, Stoitzner P, Romani N. The late endosomal adaptor molecule p14 (LAMTOR2) represents a novel regulator of Langerhans cell homeostasis. **Blood.** 2014; 123:217-27. doi: 10.1182/blood-2013-08-518555.

33. de Araujo ME, Stasyk T, Taub N, Ebner HL, Fürst B, Filipek P, Weys SR, Hess MW, Lindner H, Kremser L, **Huber LA**. Stability of the endosomal scaffold protein LAMTOR3 depends on heterodimer assembly and proteasomal degradation. **J Biol Chem**. 2013; 288:18228-42. doi: 10.1074/jbc.M112.349480.

34. Mirza MR, Rainer M, Messner CB, Güzel Y, Schemeth D, Stasyk T, Choudhary MI, **Huber LA**, Rode BM, Bonn GK. A new type of metal chelate affinity chromatography using trivalent lanthanide ions for phosphopeptide enrichment. **Analyst.** 2013; 138:2995-3004. doi: 10.1039/c3an36853j.

35. de Araujo ME, Erhart G, Buck K, Müller-Holzner E, Hubalek M, Fiegl H, Campa D, Canzian F, Eilber U, Chang-Claude J, Coassin S, Haun M, Kedenko L, Paulweber B, Reitsamer R, Himmel I, Flesch-Janys D, Lamina C, Kronenberg F, **Huber LA**, Kloss-Brandstätter A. Polymorphisms in the gene regions of the adaptor complex LAMTOR2/LAMTOR3 and their association with breast cancer risk. **PLoS On*e***. 2013; 8:e53768. doi: 10.1371/journal.pone.0053768.

36. Gronemeyer T, Wiese S, Grinhagens S, Schollenberger L, Satyagraha A, **Huber LA,** Meyer HE, Warscheid B, Just WW. Localization of Rab proteins to peroxisomes: a proteomics and immunofluorescence study. **FEBS Let***t*. 2013; 587:328-38. doi: 10.1016/j.febslet.2012.12.025.

37. Fischnaller M, Bakry R, Vallant RM, **Huber LA**, Bonn GK. C60-fullerene bound silica for the preconcentration and the fractionation of multiphosphorylated peptides**. Anal Chim Acta**. 2013; 761:92-101. doi: 10.1016/j.aca.2012.11.019.